Advertisement

Antiarrhythmic Drug Management

  • Henry H. Hsia
  • Kelly Matsuda
Chapter

Abstract

Understand the basic cellular electrophysiology. Know the classification of antiarrhythmic drugs and their electrophysiologic effects. Understand the potential mechanisms of clinically relevant arrhythmias. Identify potential pharmacologic target sites based on arrhythmia mechanisms. Know the side effect profiles of antiarrhythmic drugs. Develop a logical approach in the selection of a specific antiarrhythmic drug.

Keywords

Atrial Fibrillation Antiarrhythmic Drug Refractory Period Action Potential Duration Antiarrhythmic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Stambler B, Wood M, Ellenbogen K, Perry K, Wakefield L, VanderLugt J. Efficacy and safety of repeated intravenous doses of Ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 1996;94:1613-1621.PubMedCrossRefGoogle Scholar
  2. 2.
    Køber L, Thomsen P, Møller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet. 2000;356:2052-2058.PubMedCrossRefGoogle Scholar
  3. 3.
    Torp-Pedersen C, Møller M, Thomsen P, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341(17):857-865.PubMedCrossRefGoogle Scholar
  4. 4.
    Pedersen O, Bagger H, Keller N, Marchant B, Køber L, Torp-Pedersen C. Efficacy of Dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Sub-study. Circulation. 2001;104:292-296.PubMedCrossRefGoogle Scholar
  5. 5.
    Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation. 1991;84:1831-1851.CrossRefGoogle Scholar
  6. 6.
    Echt D, Liebson P, Mitchell L, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med. 1991;324(12): 781-788.PubMedCrossRefGoogle Scholar
  7. 7.
    Julian D, Camm A, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction. Lancet. 1997;349:667-674.PubMedCrossRefGoogle Scholar
  8. 8.
    Carins J, Connolly S, Roberts R, Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations. Lancet. 1997;349:675-682.CrossRefGoogle Scholar
  9. 9.
    Donovan K, Power B, Hockings B, Dobb G, Lee K. Intravenous flecainide versus amiodarone for recent onset atrial fibrillation. Am J Cardiol. 1995;75:693-697.PubMedCrossRefGoogle Scholar
  10. 10.
    Bertini G, Conti A, Fradella G, et al. Propafenone versus amiodarone in field treatment of primary atrial tachydysrrhythmias. J Emerg Med. 1990;8:15-20.PubMedCrossRefGoogle Scholar
  11. 11.
    Galve E, Rius T, Ballester R, et al. Intravenous amiodaropne in treatment of recently onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996;27(5):1079-1082.PubMedCrossRefGoogle Scholar
  12. 12.
    Kochiadakis G, Igoumenidis N, Solomou M, Kaleboubas M, Chlouverakis G, Vardas P. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol. 1999;83:58-61.PubMedCrossRefGoogle Scholar
  13. 13.
    Kochiadakis G, Igoumenidis N, Parthenakis F, Chlouverakis G, Vardas P. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1999;33(4):966-971.PubMedCrossRefGoogle Scholar
  14. 14.
    Peuhkurinen K, Niemela M, Ylitalo A, Linnaluoto M, Lilja M, Juvonen J. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol. 2000;85:462-465.PubMedCrossRefGoogle Scholar
  15. 15.
    Coplen S, Antman E, Berlin J, Hewitt P, Chalmers T. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation. 1990;82:1106-1116.PubMedCrossRefGoogle Scholar
  16. 16.
    ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2006;48(4):149-246.CrossRefGoogle Scholar
  17. 17.
    The AFFIRM Investigators. Survival of patients presenting with atrial fibrillation in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. N Engl J Med. 2002;347:1825-1833.CrossRefGoogle Scholar
  18. 18.
    Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation. 1991;84(2):527-539.CrossRefGoogle Scholar
  19. 19.
    Teo K, Yusuf S, Furberg C. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA. 1993;270(13): 1589-1595.PubMedCrossRefGoogle Scholar
  20. 20.
    Pratt C, Eaton T, Francis M, et al. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J. 1989;118(3):433-440.PubMedCrossRefGoogle Scholar
  21. 21.
    Pritchett E, Page R, Connolly S, Marcello S, Schnell D, Wilkinson W. Antiarrhythmic effects of Azimilide in atrial fibrillation: ­efficacy and dose-response. J Am Coll Cardiol. 2000;36(3):794-802.PubMedCrossRefGoogle Scholar
  22. 22.
    Page R, Connolly S, Wilkinson W, et al. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose response. Am Heart J. 2002;143(4):643-649.PubMedCrossRefGoogle Scholar
  23. 23.
    Dorian P, Borggrefe M, Al-Khalidi H, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patient with an implantable cardioverter defibrillator. Circulation. 2004;110:3646-3654.PubMedCrossRefGoogle Scholar
  24. 24.
    Page R, Pritchett E, Connolly S, Wilkinson W. Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias. J Cardiovasc Electrophysiol. 2008;19(2):172-177.PubMedCrossRefGoogle Scholar
  25. 25.
    Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007;41:599-605.PubMedCrossRefGoogle Scholar
  26. 26.
    Touboul P, Brugada J, Capuccic A, Crijns H, Edvardssone N, Hohnloserf S. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481-1487.PubMedCrossRefGoogle Scholar
  27. 27.
    Singh B, Connolly S, Crijns H, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.PubMedCrossRefGoogle Scholar
  28. 28.
    Hohnloser S, Crijns H, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678.PubMedCrossRefGoogle Scholar
  29. 29.
    Køber L, Torp-Pedersen C, McMurray J, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687.PubMedCrossRefGoogle Scholar
  30. 30.
    Cheng J. Vernakalant in the management of atrial fibrillation. Ann Pharmacother. 2008;42:533-542.PubMedCrossRefGoogle Scholar

Additional Reading

  1. Reiser HJ, Horowitz LN, eds. Mechanism and Treatment of Cardiac Arrhythmias: Relevance of Basic Studies to Clinical Management. Baltimore, MD: Urban & Schwarzenberg; 1985.Google Scholar
  2. Opie L. The Heart, Physiology, Metabolism, Pharmacology, Therapy. New York: Grune & Stratton; 1987.Google Scholar
  3. Podrid PJ, Kowey PR, eds. Handbook of Cardiac Arrhythmia. Philadelphia: Williams & Wilkins; 1996.Google Scholar
  4. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation. Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines, developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2006;48(4):e149-e246.Google Scholar
  5. Josephson ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations. 2nd ed. Philadelphia: Lea & Febiger; 1993.Google Scholar
  6. Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: W.B. Saunders; 2000.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Henry H. Hsia
    • 1
  • Kelly Matsuda
    • 2
  1. 1.Department of Cardiovascular MedicineStanford University Medical CenterStanfordUSA
  2. 2.Department of PharmacyStanford Medical CenterStanfordUSA

Personalised recommendations